Fulgent Income Statement Research

FLGT Stock

USD 21.79 0.52 2.44%

Most accounts from Fulgent Genetics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Fulgent Genetics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Fulgent Genetics Valuation and Fulgent Genetics Correlation analysis.

For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.

At this time, Fulgent Genetics' Cost Of Revenue is comparatively stable compared to the past year. Total Operating Expenses is likely to gain to about 180.5 M in 2024, despite the fact that Net Loss is likely to grow to (61.7 M).

For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.At this time, Fulgent Genetics' Cost Of Revenue is comparatively stable compared to the past year. Total Operating Expenses is likely to gain to about 180.5 M in 2024, despite the fact that Net Loss is likely to grow to (61.7 M).

	2021	2022	2023	2024 (projected)
Gross Profit	777.1M	366.9M	96.6M	179.1M
Total Revenue	992.6M	619.0M	289.2M	266.7M

Gross Profit Total Revenue

Fulgent Genetics income statement Correlations

	Discontinued Operations	Depreciation And Amortization	Selling General Administrative	Selling And Marketing Expenses	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Interest Income	Extraordinary Items	Tax Provision	Net Interest Income	Non Operating Income Net Other	Reconciled Depreciation
Discontinued Operations		0.44	0.53	0.6	0.51	0.46	0.53	0.26	0.29	0.26	0.59	0.31	0.57	0.57	0.12	-0.31	0.1	0.31	0.46	1.0	0.34	0.62	0.73	0.42
Depreciation And Amortization	0.44		0.83	0.88	0.27	0.15	0.87	-0.27	-0.23	-0.27	0.92	-0.16	0.71	0.86	-0.5	-0.95	-0.57	-0.1	0.98	0.44	-0.08	0.96	0.75	0.9
Selling General Administrative	0.53	0.83		0.98	0.66	0.53	0.98	0.11	0.18	0.11	0.95	0.2	0.95	0.99	-0.1	-0.64	-0.15	0.26	0.78	0.53	0.28	0.84	0.88	0.95
Selling And Marketing Expenses	0.6	0.88	0.98		0.67	0.56	0.97	0.11	0.2	0.11	0.99	0.22	0.95	0.99	-0.12	-0.72	-0.17	0.3	0.83	0.59	0.32	0.91	0.9	0.92
Total Revenue	0.51	0.27	0.66	0.67		0.98	0.56	0.56	0.86	0.56	0.63	0.61	0.85	0.67	0.44	-0.1	0.44	0.9	0.24	0.5	0.91	0.41	0.69	0.39
Gross Profit	0.46	0.15	0.53	0.56	0.98		0.43	0.59	0.92	0.59	0.52	0.63	0.76	0.55	0.49	0.0	0.5	0.95	0.12	0.46	0.96	0.3	0.59	0.24
Other Operating Expenses	0.53	0.87	0.98	0.97	0.56	0.43		0.14	0.07	0.14	0.93	0.25	0.9	0.97	-0.08	-0.67	-0.14	0.15	0.81	0.53	0.17	0.87	0.83	0.97
Operating Income	0.26	-0.27	0.11	0.11	0.56	0.59	0.14		0.68	1.0	0.0	0.99	0.29	0.1	0.96	0.46	0.94	0.61	-0.31	0.26	0.6	-0.13	0.03	-0.05
Net Income From Continuing Ops	0.29	-0.23	0.18	0.2	0.86	0.92	0.07	0.68		0.68	0.16	0.67	0.47	0.2	0.66	0.33	0.69	0.99	-0.24	0.28	0.99	-0.06	0.29	-0.13
Ebit	0.26	-0.27	0.11	0.11	0.56	0.59	0.14	1.0	0.68		0.0	0.99	0.29	0.1	0.96	0.46	0.94	0.61	-0.31	0.26	0.6	-0.13	0.03	-0.05
Research Development	0.59	0.92	0.95	0.99	0.63	0.52	0.93	0.0	0.16	0.0		0.1	0.92	0.97	-0.24	-0.8	-0.29	0.27	0.88	0.59	0.3	0.94	0.91	0.89
Ebitda	0.31	-0.16	0.2	0.22	0.61	0.63	0.25	0.99	0.67	0.99	0.1		0.38	0.2	0.93	0.36	0.89	0.61	-0.21	0.31	0.61	-0.03	0.11	0.06
Cost Of Revenue	0.57	0.71	0.95	0.95	0.85	0.76	0.9	0.29	0.47	0.29	0.92	0.38		0.96	0.09	-0.52	0.05	0.54	0.66	0.57	0.56	0.77	0.89	0.81
Total Operating Expenses	0.57	0.86	0.99	0.99	0.67	0.55	0.97	0.1	0.2	0.1	0.97	0.2	0.96		-0.12	-0.68	-0.17	0.29	0.81	0.56	0.31	0.88	0.9	0.93
Income Before Tax	0.12	-0.5	-0.1	-0.12	0.44	0.49	-0.08	0.96	0.66	0.96	-0.24	0.93	0.09	-0.12		0.68	0.99	0.56	-0.54	0.12	0.55	-0.37	-0.15	-0.25
Total Other Income Expense Net	-0.31	-0.95	-0.64	-0.72	-0.1	0.0	-0.67	0.46	0.33	0.46	-0.8	0.36	-0.52	-0.68	0.68		0.74	0.19	-0.96	-0.31	0.17	-0.88	-0.59	-0.72
Net Income	0.1	-0.57	-0.15	-0.17	0.44	0.5	-0.14	0.94	0.69	0.94	-0.29	0.89	0.05	-0.17	0.99	0.74		0.59	-0.6	0.1	0.58	-0.43	-0.17	-0.32
Income Tax Expense	0.31	-0.1	0.26	0.3	0.9	0.95	0.15	0.61	0.99	0.61	0.27	0.61	0.54	0.29	0.56	0.19	0.59		-0.11	0.31	1.0	0.05	0.37	-0.05
Interest Income	0.46	0.98	0.78	0.83	0.24	0.12	0.81	-0.31	-0.24	-0.31	0.88	-0.21	0.66	0.81	-0.54	-0.96	-0.6	-0.11		0.46	-0.09	0.92	0.69	0.85
Extraordinary Items	1.0	0.44	0.53	0.59	0.5	0.46	0.53	0.26	0.28	0.26	0.59	0.31	0.57	0.56	0.12	-0.31	0.1	0.31	0.46		0.34	0.62	0.73	0.42
Tax Provision	0.34	-0.08	0.28	0.32	0.91	0.96	0.17	0.6	0.99	0.6	0.3	0.61	0.56	0.31	0.55	0.17	0.58	1.0	-0.09	0.34		0.08	0.4	-0.03
Net Interest Income	0.62	0.96	0.84	0.91	0.41	0.3	0.87	-0.13	-0.06	-0.13	0.94	-0.03	0.77	0.88	-0.37	-0.88	-0.43	0.05	0.92	0.62	0.08		0.87	0.85
Non Operating Income Net Other	0.73	0.75	0.88	0.9	0.69	0.59	0.83	0.03	0.29	0.03	0.91	0.11	0.89	0.9	-0.15	-0.59	-0.17	0.37	0.69	0.73	0.4	0.87		0.76
Reconciled Depreciation	0.42	0.9	0.95	0.92	0.39	0.24	0.97	-0.05	-0.13	-0.05	0.89	0.06	0.81	0.93	-0.25	-0.72	-0.32	-0.05	0.85	0.42	-0.03	0.85	0.76

Click cells to compare fundamentals

Fulgent Genetics Account Relationship Matchups

Fulgent Genetics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	2.2M	354K	6.2M	5.5M	37M	38.9M
Total Revenue	32.5M	421.7M	992.6M	619.0M	289.2M	266.7M
Gross Profit	18.4M	331.9M	777.1M	366.9M	96.6M	179.1M
Operating Income	(428K)	290.2M	104.3M	178.5M	(75.3M)	(71.5M)
Ebit	(428K)	290.2M	104.3M	178.5M	(75.3M)	(71.5M)
Research Development	6.5M	11.6M	24.2M	28.9M	41.4M	43.5M
Ebitda	1.7M	293.1M	106.0M	191.0M	(43.5M)	(41.4M)
Cost Of Revenue	14.1M	89.8M	215.5M	252.1M	192.6M	202.2M
Income Before Tax	409K	291.7M	104.3M	184.0M	(174.1M)	(165.4M)
Net Income	366K	214.3M	104.3M	143.4M	(167.8M)	(159.4M)
Income Tax Expense	43K	72.5M	174.8M	42.1M	1.2M	1.1M
Interest Income	837K	1.5M	1.3M	5.5M	18.6M	19.5M
Tax Provision	43K	72.5M	174.8M	42.1M	2.6M	2.5M
Net Interest Income	837K	1.5M	1.3M	5.5M	18.6M	19.5M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Fulgent Genetics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Fulgent Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Fulgent Genetics Stock. Highlighted below are key reports to facilitate an investment decision about Fulgent Genetics Stock:

How To Invest In Fulgent

Details

Is Fulgent Stock a good investment?

Details

What is Fulgent Genetics' Net Worth?

Details

Largest Health Care Providers & Services Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Fulgent Genetics Valuation and Fulgent Genetics Correlation analysis.

For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.

Note that the Fulgent Genetics information on this page should be used as a complementary analysis to other Fulgent Genetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Complementary Tools for Fulgent Stock analysis

When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.

	Commodity Directory Find actively traded commodities issued by global exchanges
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Volatility Analysis Get historical volatility and risk analysis based on latest market data

Is Fulgent Genetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulgent Genetics. If investors know Fulgent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulgent Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.99)

Earnings Share

(5.56)

Revenue Per Share

9.635

Quarterly Revenue Growth

(0.03)

Return On Assets

(0.03)

The market value of Fulgent Genetics is measured differently than its book value, which is the value of Fulgent that is recorded on the company's balance sheet. Investors also form their own opinion of Fulgent Genetics' value that differs from its market value or its book value, called intrinsic value, which is Fulgent Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulgent Genetics' market value can be influenced by many factors that don't directly affect Fulgent Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Fulgent Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulgent Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulgent Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Fulgent Income Statement Research

Fulgent Genetics income statement Correlations

Fulgent Genetics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Fulgent Genetics income statement Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Fulgent Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Extraordinary Items	+ 1.0	Discontinued Operations
Ebit	+ 1.0	Operating Income
Tax Provision	+ 1.0	Income Tax Expense
Total Operating Expenses	+ 0.99	Selling General Administrative
Research Development	+ 0.99	Selling And Marketing Expenses
Total Operating Expenses	+ 0.99	Selling And Marketing Expenses

Interest Income	- 0.96	Total Other Income Expense Net
Total Other Income Expense Net	- 0.95	Depreciation And Amortization
Net Interest Income	- 0.88	Total Other Income Expense Net
Total Other Income Expense Net	- 0.8	Research Development
Reconciled Depreciation	- 0.72	Total Other Income Expense Net
Total Other Income Expense Net	- 0.72	Selling And Marketing Expenses